Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
PLX
PLX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PLX News
Elfabrio's New Dosing Regimen Approved by EU
1d ago
Newsfilter
Elfabrio's New Dosing Regimen Approved by EU
1d ago
Globenewswire
Ellomay Capital Shareholders Sell Stakes and Board Restructuring
6d ago
Newsfilter
Protalix's New Dosing Regimen Recommended for Approval
Jan 30 2026
stocktwits
EMA Endorses New Dosing Regimen for Elfabrio
Jan 30 2026
seekingalpha
CHMP Endorses New Treatment Regimen for Fabry Disease
Jan 30 2026
Globenewswire
Elfabrio's New Dosing Regimen Receives Positive Opinion from CHMP
Jan 30 2026
Globenewswire
Elfabrio's New Dosing Regimen Receives Positive Opinion from CHMP
Jan 30 2026
Newsfilter
Pluxee Reports Q1 2026 Revenues Up 9% to €308 Million
Jan 07 2026
Globenewswire
Protalix Advances PRX-115 for Uncontrolled Gout Amid Rising Global Prevalence
Jan 05 2026
PRnewswire
Protalix and Secarna Collaborate on ASO Therapies for Rare Kidney Disorders
Dec 17 2025
NASDAQ.COM
HC Wainwright & Co. Reaffirms Buy Rating for Protalix BioTherapeutics, Adjusts Price Target to $12
Nov 21 2025
Benzinga
Chiesi Global Rare Diseases and Protalix BioTherapeutics Request EMA Re-evaluation of Negative Opinion on Elfabrio (pegunigalsidase alfa) Four-Week Dosing Regimen in the EU
Nov 03 2025
Globenewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
Oct 28 2025
PRnewswire
Chiesi Global Rare Diseases and Protalix Biotherapeutics Respond to CHMP's Negative Opinion on Elfabrio® (pegunigalsidase alfa) Four-Week Dosing Schedule in the EU
Oct 16 2025
Globenewswire
Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript
Aug 14 2025
Newsfilter
Show More News
